Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-1247
Abstract: Purpose: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to… read more here.
Keywords: fusion protein; anti cd3; metastatic melanoma; patients metastatic ... See more keywords
Abstract 2958: BSI-508, a novel bispecific fusion molecule targeting PD1 and CD47 for cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2958
Abstract: Introduction: While anti-PD1/PDL1 mAbs have shown success in the market only a small fraction of patients actually benefit from the therapies. Novel approaches to improve outcomes for patients who are resistant or refractory to current… read more here.
Keywords: bispecific fusion; fusion; anti pd1; molecule ... See more keywords
Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV
Sign Up to like & getrecommendations! Published in 2019 at "Antibodies"
DOI: 10.3390/antib8040053
Abstract: In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct. However, to the best of our… read more here.
Keywords: peptide bispecific; bispecific fusion; antibody; mers cov ... See more keywords